Drug intelligence / Profile preview

HKUB-004

Development stage: Preclinical
Lead developer: Hong Kong Universal Biologicals
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

HKUB-004 is a preclinical-stage viral vector vaccine candidate developed by Hong Kong Universal Biologicals for the prevention of Respiratory Syncytial Virus (RSV) infection. The vaccine utilizes the company's proprietary Innovative Viral Vector Platform, which is designed to induce robust immune responses against RSV antigens. By leveraging this viral vector technology, HKUB-004 aims to provide a protective immune profile to prevent RSV-associated respiratory disease. The program is currently in the preclinical phase of development.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on HKUB-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HKUB-004.

Explore the full profile